RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
+13.86%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$5.94B
AUM Growth
+$5.94B
(-0.87%)
Cap. Flow
-$357M
Cap. Flow
% of AUM
-6.02%
Top 10 Holdings %
Top 10 Hldgs %
66.2%
Holding
90
New
5
Increased
9
Reduced
10
Closed
27
Top Buys
| 1 |
Cidara Therapeutics
CDTX
|
$111M |
| 2 |
Taysha Gene Therapies
TSHA
|
$29.3M |
| 3 |
Avidity Biosciences
RNA
|
$27.4M |
| 4 |
HNGE
Hinge Health, Inc.
HNGE
|
$15.5M |
| 5 |
Tyra Biosciences
TYRA
|
$14.9M |
Top Sells
| 1 |
JBIO
Jade Biosciences, Inc. Common Stock
JBIO
|
$81.2M |
| 2 |
Apogee Therapeutics
APGE
|
$58.6M |
| 3 |
Zai Lab
ZLAB
|
$46.8M |
| 4 |
Day One Biopharmaceuticals
DAWN
|
$45.6M |
| 5 |
UroGen Pharma
URGN
|
$35.5M |
Sector Composition
| 1 | Healthcare | 99.82% |
| 2 | Financials | 0.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Werewolf Therapeutics
HOWL
$61.3M
| $7.28M | 0.12% |
6,681,307
+536,426
| +9% | +$585K |
|
|
BBNX
52
Beta Bionics, Inc. Common Stock
BBNX
$840M
| $7.28M | 0.12% |
500,000
| – | – |
|
53
CytomX Therapeutics
CTMX
$343M
| $6.04M | 0.1% |
2,661,331
+1,661,331
| +166% | +$3.77M |
|
54
10x Genomics
TXG
$1.67B
| $5.5M | 0.09% |
475,343
-1,468,904
| -76% | -$17M |
|
55
Surrozen
SRZN
$107M
| $5.39M | 0.09% |
602,626
-76,504
| -11% | -$684K |
|
56
GeneDx Holdings
WGS
$3.7B
| $5.36M | 0.09% |
+58,044
| New | +$5.36M |
|
57
Avalo Therapeutics
AVTX
$137M
| $4.66M | 0.08% |
932,973
-34,027
| -4% | -$170K |
|
58
Adicet Bio
ACET
$61.2M
| $4.6M | 0.08% |
7,541,000
| – | – |
|
|
MBX
59
MBX Biosciences, Inc. Common Stock
MBX
$492M
| $4.31M | 0.07% |
377,841
-1,133,493
| -75% | -$12.9M |
|
60
Protara Therapeutics
TARA
$125M
| $3.15M | 0.05% |
1,039,295
-2,360,705
| -69% | -$7.15M |
|
61
NewAmsterdam Pharma Company N.V. Warrant
NAMSW
$62M
| $2.67M | 0.04% |
333,333
| – | – |
|
62
Acadia Healthcare
ACHC
$2.16B
| $2.03M | 0.03% |
89,262
-127,738
| -59% | -$2.9M |
|
63
InflaRx
IFRX
$117M
| $1.56M | 0.03% |
+1,973,233
| New | +$1.56M |
|
64
Aclaris Therapeutics
ACRS
$219M
| – | – |
-4,666,667
| Closed | -$7.14M |
|
65
Alector
ALEC
$273M
| – | – |
-9,695,228
| Closed | -$11.9M |
|
|
66
Apogee Therapeutics
APGE
$2.26B
| – | – |
-1,569,491
| Closed | -$58.6M |
|
67
Astria Therapeutics
ATXS
$381M
| – | – |
-5,105,213
| Closed | -$27.3M |
|
|
BCYC
68
Bicycle Therapeutics
BCYC
$496M
| – | – |
-1,093,477
| Closed | -$9.28M |
|
|
69
Day One Biopharmaceuticals
DAWN
$764M
| – | – |
-5,755,577
| Closed | -$45.6M |
|
|
DRUG
70
Bright Minds Biosciences
DRUG
$283M
| – | – |
-206,427
| Closed | -$7.45M |
|
71
EyePoint Pharmaceuticals
EYPT
$824M
| – | – |
-3,181,818
| Closed | -$17.2M |
|
72
Glaukos
GKOS
$5.37B
| – | – |
-190,256
| Closed | -$18.7M |
|
73
Humacyte
HUMA
$228M
| – | – |
-3,312,356
| Closed | -$5.65M |
|
74
IDEAYA Biosciences
IDYA
$2.23B
| – | – |
-1,347,252
| Closed | -$22.1M |
|
75
Immatics
IMTX
$661M
| – | – |
-1,750,000
| Closed | -$7.89M |
|